Introduction
Gastric adenocarcinoma is the fourth most common cancer worldwide [1] , but the male predominance in the incidence of this tumor remains unexplained. For every female patient, two to three males are affected [1] . It has been proposed that estrogen might protect women against this cancer [2] , a hypothesis supported by some epidemiological studies [2] [3] [4] [5] [6] . A reported 10-to 15-year delay in the onset of gastric adenocarcinoma, exclusively of the intestinal type in females, suggests a protective effect of endogenous estrogen [2] . If estrogen prevents the occurrence of the intestinal type of gastric adenocarcinoma, a biological mechanism needs to be established. The effects of estrogen on the cell are typically mediated by estrogen receptors (ERs). Two types of ERs have been identifi ed; ERalpha (α) [7] and ERbeta (β) [8] , and both have been observed in gastric [9, 10] as well as other tissue. Moreover, a splicing variant of ERβ has recently been discovered, i.e., ERβcx [11] , but the possible occurrence of this receptor has not previously been studied in gastric tumors. We hypothesized that high current endogenous estrogen exposure decreases the isolated risk of developing the intestinal type of gastric adenocarcinoma, and not the diffuse type, and that this effect is mediated by the action of estrogen on gastric ERs. To address these hypotheses, we studied samples of gastric adenocarcinoma tissues from patients in a population-based cohort with high and low endogenous estrogen exposure, and compared the distribution of the intestinal and diffuse histological type and ERs α, β, and βcx in randomly selected intestinal tumors.
Patients, mate rials, and methods

Study design
This was a population-based cohort study of patients with gastric adenocarcinoma, diagnosed in the county of Stockholm during the period 1958 to 2004 inclusive. The patients were identifi ed in the Swedish Cancer Register and categorized into three groups with regard to their endogenous estrogen exposure at the time of the diagnosis: (1) females younger than 50 years of age, i.e., before the menopause, representing the group of "exposed women"; (2) males younger than 50 years, representing the group of "unexposed men"; and (3) females over the age of 70 years, i.e., at least 20 years after the menopause, representing the group of "unexposed women". Histopathological evaluation was conducted to verify the diagnosis of gastric adenocarcinoma and to further classify the adenocarcinomas into the intestinal or diffuse type. Finally, in randomly selected cases of intestinal adenocarcinoma, the occurrence of ERs α, β, and βcx was determined, using immunohistochemistry.
Identifi cation of study participants
All clinicians and pathologists in Sweden are obliged to report all newly diagnosed cancer cases to the Swedish Cancer Register. This Register has been shown to have a completeness rate of 98% for gastric cancer [12] . For the registration of cancer diagnoses, the Register has used the seventh revision of the International Classifi cation of Diseases (ICD) (WHO/HS/CANC/24.1 Code for anatomical location) between 1958-1986. For the years 1987-1992, the ICD-9 coding system has been followed (WHO ninth revision 1976); for the period 1993-2004, the ICD-O-2/ICD-10 (ICD for Oncology, second edition; WHO Geneva 1990) has been used; and since 2005, the ICD-O/3 (third edition; WHO Geneva 2000) has been used. The Swedish Cancer Register translates the different classifi cations to ICD-7 in order to be able to follow the incidence of various cancer forms.
The following ICD codes were used to identify the gastric cancer cases in the Register: 151 (ICD-7); 151.0-9 (ICD-9), and C16.0-9 (ICD-10). After restriction of the Register to the county of Stockholm, 364 patients with gastric cancer were identifi ed in the "exposed women" group, 396 patients in the group of "unexposed men", and 3008 patients in the group of "unexposed women".
Determination of the type of gastric adenocarcinomaintestinal or diffuse
We selected the latest consecutive 150 cases in each group as eligible for further evaluation. Among these 450 cases, we requested histological sections from biopsies and surgical specimens of the 416 cases fi led at the six major pathology departments in the county of Stockholm. Of these, we retrieved histological material from 356 cases (86%). Two investigators (E. C. and C. A. R.), blinded to the group categorization (age and sex) of the patients, reviewed all specimens. They verifi ed or refuted the gastric adenocarcinoma diagnosis and categorized each adenocarcinoma histologically into the intestinal or diffuse type in accordance with the Laurén classifi cation [13] . Specimens of mixed histological types were classifi ed according to Ming as being of the diffuse type [14] . The 289 patients (81%) with a verifi ed gastric adenocarcinoma and suffi cient histological material for evaluation were included for fi nal analysis. Of these, 101 (35%) had the intestinal type of gastric adenocarcinoma.
Evaluation of estrogen receptors
Among the 101 cases of intestinal gastric adenocarcinoma that were evaluated histopathologically, 45 cases were randomly selected for immunohistochemical analysis of the ERs α, β, and βcx. Because the specimens from the selected tumors were mainly endoscopic biopsy samples, only a limited amount of tissue was available for immunohistochemistry in some cases. Consecutive sections, each 4-μm-thick, were cut from paraffi nembedded material. One investigator (E. C.) performed the immunohistochemistry according to a previously described protocol [15] . In brief, we used the following antibodies and dilutions: rabbit anti ERα from Santa Cruz Biotechnology (Santa Cruz, CA, USA; 1: 120), and chicken polyclonal antibody anti-ERβ 503 IgY (1: 200) and anti ERβcx sheep anticlonal antibody (1: 200; both produced at our laboratory).
ERβ antibody was raised against human ERβ protein without the N-terminal amino acids. It was raised in hens and the IgY was purifi ed from egg yolks. This antibody has been extensively used in many laboratories throughout the world. The cx antibody was raised in sheep against the cx peptide; this antibody has also been used in many laboratories. Positive controls for ERβ IgY are mammary gland and ovary. Positive controls for cx are cell lines expressing ERβ cx. Negative controls: for each antibody, the antigens were coupled to sepharose beads and shaken with the antibody for 20 min in the cold. The beads were removed and the supernatant used in immunohistochemistry.
For our study human breast tissue was obtained for a positive control. Secondary antibodies were applied, after which the slides were incubated with avidin biotin complex (ABC; Vector Laboratories, Burlingame, CA, USA) and colored with 3, 3′-diaminobenzidine tetrahydrochloride substrate (DAKO, Copenhagen, Denmark). The sections were fi nally counterstained with Mayer's hematoxylin.
Immunohistochemical evaluation was performed according to the recommendation of Wang et al. [16] by two investigators (E. C. and C. A. R.) who were blinded to the group categorization (age and sex) of the patients. According to Wang et al. [16] the selection of one fi eld is better than when results are based on the average count of three or fi ve fi elds, and therefore areas with the highest degree of ER expression were evaluated, both in tumor and nontumor tissue. Specimens with 50% or more of the cells, in a high-power fi eld, positive for ERs were considered positive.
ERs are mainly found in the nucleus [17] , but immunoreactivity in the cytoplasm has also been observed [18] . In our study, sections with positive nuclear immunoreactivity were considered as positive. Cytoplasmic (granular) staining was observed in some samples. In particular, positive cytoplasmatic staining with βcx antibody was specifi c because it could be quenched when the antibody was preabsorbed with the βcx antigen. Although the signifi cance remains to be determined, the staining was included because ERβcx escorts ERα to the proteasome for degradation and its presence in cytoplasmic granules may indicate increases in the degradation of ERα [19] . In addition, we examined both the gastric cancer tissue and the adjacent nontumor tissue, if present in the section.
Statistical analysis
Fisher's exact test was used to compare the frequency distributions of the three estrogen receptors between the three patient groups. Logistic regression was utilized to estimate relative risks, expressed as odds ratios (ORs) with 95% confi dence intervals (CIs). All statistical analyses were performed with STATA version 9.2 (Stata, College Station, TX, USA). All reported probabilities (P values) were two-sided, and those less than 0.05 were considered statistically signifi cant.
Ethics
The regional ethics committee at Karolinska Institutet in Stockholm, Sweden, approved the study. Table 1 shows the distribution of the histological types of gastric adenocarcinoma in the three study groups. The occurrence of the intestinal type of gastric adenocarcinoma was lowest among the "exposed women" (11%) and highest among the "unexposed women" (53%). Compared to "exposed women" the occurrence of the intestinal type was statistically signifi cantly more than four times and nine times higher among "unexposed men" (OR, 4.7; 95% CI, 2.2-10.3) and "unexposed women" (OR, 9.1; 95% CI, 4.3-19.6), respectively. Table 2 shows the occurrence of cases with positive nuclear and non-nuclear ER staining in the intestinal type of gastric adenocarcinoma tissue. The tumors of the "unexposed men" had a higher frequency of ERα-positive nuclear staining (40%) compared to "exposed women" (25%; see example in Fig. 1A ), but the difference was not statistically signifi cant. The frequencies of non-nuclear ERα and ERβ were lower in "unexposed men" than in "exposed women", and the difference regarding ERα was statistically signifi cant (P = 0.035). The distribution of both nuclear and non-nuclear ERs was similar in "exposed women" and "unexposed women". Although no cases of nuclear staining of ERβcx were found, a total of four (9%) cases showed ERβcx-positive non-nuclear staining. Relative risk is expressed as odds ratios (ORs) with 95% confi dence intervals (CIs) Exposed women: less than 50 years of age; Unexposed men: less than 50 years of age; Unexposed women: more than 70 years of age
Results
Histological type of gastric adenocarcinoma
Occurrence of a, b, and bcx estrogen receptors in adenocarcinoma tissue
Occurrence of a, b, and bcx estrogen receptors in nontumor gastric mucosa Table 3 shows the number of cases with positive nuclear and non-nuclear ER staining in the gastric mucosa adjacent to the gastric tumor among patients with intestinal gastric adenocarcinoma (see examples in Fig. 1B-D) . The results were similar to those found for tumor tissue, except for a lower occurrence of ERβ among unexposed women ( Table 3 ). The occurrence of positive nonnuclear ERβcx staining (see examples in Fig. 1C, D) seemed higher in the nontumor tissue. No statistically signifi cant differences were found between the comparison groups.
Comparison of estrogen receptors in the adenocarcinoma and nontumor gastric mucosa
In all three groups of patients, the percentage of ERα-positive cells was higher in the adenocarcinoma tissue than in the adjacent tissue. The opposite trend was noted for ERβ and βcx; that is, positive β and βcx receptors were less frequent (or nonexistent) in the gastric adenocarcinoma tissue than in nontumor tissue.
Discussion
This study indicated that women exposed to high levels of endogenous estrogen are at lower risk of developing Cases of intestinal gastric adenocarcinoma investigated immunohistochemically with regard to the presence of estrogen receptors (ER) α, β, and βcx. Exposed women: less than 50 years of age; unexposed men: less than 50 years of age; unexposed women: more than 70 years of age Fig. 1 . A Gastric adenocarcinoma of the intestinal type expressing nuclear estrogen receptor α, in an estrogen-exposed woman. ERα, ×60. B Pyloric glands adjacent to intestinal gastric adenocarcinoma (not shown), expressing nuclear estrogen receptor β, in a woman not exposed to estrogen. ERβ, ×40. C Pyloric glands adjacent to intestinal gastric adenocarcinoma (not shown), expressing estrogen receptor βcx in supranuclear granules, in a woman not exposed to estrogen. ERβcx, ×40. D Nontumor glands adjacent to intestinal gastric adenocarcinoma (not shown) expressing estrogen receptor βcx in supranuclear granules, in a man not exposed to estrogen. ERβcx, ×40
the intestinal type of gastric adenocarcinoma, compared to less exposed women or men. No substantial differences in the presence of ERα, β, or βcx were found between the three comparison groups with the intestinal type of gastric adenocarcinoma, either in the tumor or in the adjacent tissue. For the fi rst time, ERβcx was identifi ed in gastric tissue. Some methodological aspects of this study deserve consideration. Selection bias was counteracted by the population-based design, all patients being identifi ed from the virtually complete Swedish Cancer Register [12] . The high participation rate regarding the collected tumor material also diminished the risk of selection bias. Tumor misclassifi cation was reduced by our review, in which the gastric adenocarcinoma diagnosis was verifi ed in all study participants. The histological evaluation, the immunohistochemical laboratory work, and the subsequent assessment regarding the presence of ERs were all conducted blindly with regard to the estrogen exposure status of each patient, decreasing the risk of systematic bias. A disadvantage of the study is the small number of intestinal-type gastric adenocarcinoma cases in the ER analyses. Hence, our results regarding the differences in the presence of ERs between the comparison groups must be interpreted with caution. Moreover, the lack of information regarding risk factors for gastric adenocarcinoma prohibited adjustment for potential confounding factors. Other studies have shown, however, that the distribution of the intestinal and diffuse types of gastric adenocarcinoma is not affected by Helicobacter pylori infection [20, 21] , tobacco use [22] , intake of alcoholic beverages [22] , intake of fruits or vegetables [23] , or occupational exposure [24] , and these factors should not therefore act as confounders in our analyses of histological type. A high socioeconomic status may, however, lower the risk of developing the intestinal type of adenocarcinoma [25] . The relation between these risk factors and ER status has never been evaluated and it is therefore not possible to know whether they would have affected our results.
Some epidemiological studies indicate that exogenous estrogen has a protective effect on the risk of gastric adenocarcinoma development. In a Swedish cohort study of prostate cancer patients, the risk of gastric adenocarcinoma was lower among those who were treated with estrogen [5] . In a cohort of postmenopausal women in the United Kingdom, a decreased risk of gastric adenocarcinoma was found among users of hormone replacement therapy [4] , which is in line with an Italian study [26] . In a cohort study of breast cancer patients in Sweden, women who had received antiestrogen treatment with tamoxifen had an increased risk of subsequently developing gastric adenocarcinoma compared to patients without such treatment [3] .
With regard to endogenous estrogen exposure, a global pattern with a male predominance unique for gastric adenocarcinoma of the intestinal type and with a 10-to 15-year delay in its incidence in women has been reported [2] . A Canadian study offers further support to the hypothesis that high endogenous estrogen exposure reduces the risk of gastric cancer, in particular of the intestinal type [6] . Moreover, in a recently published Chinese prospective study in which a large cohort of women was followed up, the results suggested that female hormones play a protective role against the risk of gastric cancer [27] . Others too have found similar associations; for instance, a longer fertility life has been reported to decrease the risk of gastric cancer [28] [29] [30] [31] , although not all agree with this fi nding [32] . Our results regarding the differences in the distribution of the two histological types of gastric adenocarcinoma in the three patient groups gain support from some previous studies [33] [34] [35] . Thus, the hypothesis that endogenous estrogen exposure decreases the risk of the intestinal type of gastric adenocarcinoma might be true, but the mechanisms underlying this effect are unclear. (13) 1 (3) 8 (24) 11 (34) 11 (34) Cases of intestinal gastric adenocarcinoma investigated immunohistochemically with regard to the presence of estrogen receptors (ER) α, β, and βcx in the nontumor gastric mucosa (adjacent to the gastric tumor). Exposed women: less than 50 years of age; unexposed men: less than 50 years of age; unexposed women: more than 70 years of age
We hypothesized that the protective effect of estrogen on gastric intestinal adenocarcinoma development is mediated by ERs, a concept that has not, to our knowledge, been tested previously. The reported decrease in the risk of colorectal cancer among women using postmenopausal hormone therapy [36] [37] [38] , might, however, be mediated by ERβ [39] , the predominant ER identifi ed in colonic epithelium [39, 40] . Nevertheless, our results do not provide any strong evidence that ERs are mediators of the possible protective effect of endogenous estrogen exposure. In a previous study of ERs in gastric cancer, a decreased ER-positive rate with age was found in women [41] , but all types of gastric cancer were included in the analysis. In another study, no sex differences were observed with regard to ER expression, but the frequency of ER-positive cancers was higher in postmenopausal than in premenopausal women [42] . The number of cases was small, however, and no distinction was made between the two histological types of gastric adenocarcinoma. Thus, the potential role of ERs in mediating the low occurrence of gastric adenocarcinoma of the intestinal type remains uncertain.
We did, however, fi nd differences in the occurrence of ER-positivity between tumor and nontumor adjacent gastric tissue in all three patient groups. The decreased expression of ERβ and βcx in the gastric adenocarcinoma tissue compared to the nontumor gastric mucosa adjacent to the tumor is in accordance with reports of decreased expression of ERβ in breast [43] and prostate [44] cancer cells, as well as in gastric adenocarcinoma [45] . In addition, we found increased expression of ERα in gastric adenocarcinoma tissue compared to nontumor tissue, which is in line with the results of a study of breast cancer [43] . Interestingly, we also report, for the fi rst time, the existence of ERβcx in the stomach. ERβcx is known to be expressed in the thymus, ovaries, testis, and prostate [11, 46] , and in the breast [47] . ERβcx does not bind estrogen; instead, it inhibits ERα from binding DNA, while it does not infl uence ERβ [46] . The significance of the presence of ERβcx in gastric adenocarcinoma remains to be further investigated.
In this study we combined population-based data collection with experimental analyses to try to elucidate in greater detail the possible sex hormonal involvement in the male predominance in the incidence of gastric adenocarcinoma. Clearly, more studies are needed to establish the roles of endogenous and exogenous estrogen exposure and ERs. Gastric cancer remains the second most common cause of cancer death worldwide [1] , emphasizing the importance of understanding its etiology. Speculatively, future research that can establish the potential role of estrogen and ERs in relation to gastric adenocarcinoma might open the way for adjuvant or preventive strategies in the treatment of this cancer, e.g., through the action of more selective ER modulators, and probably of specifi c ERβ agonists, because these receptors promote epithelial differentiation [39] .
In conclusion, this epidemiological and experimental study provided evidence in favor of the hypothesis that women currently exposed to endogenous estrogen are at decreased risk of developing the intestinal type of gastric adenocarcinoma. Because no material differences in the distribution of ERs in the intestinal type of gastric adenocarcinoma with regard to endogenous estrogen exposure status were found, the role of ERs in explaining this sex difference remains uncertain. Nevertheless, our data indicate that the expression of ERs is altered in gastric adenocarcinoma compared to that in nontumor gastric mucosa, and for the fi rst time the existence of ERβcx in the stomach is reported.
